Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

NCT02582320 · clinicaltrials.gov ↗

COMPLETED

Status

264

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Ibrutinib

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto